TRex Bio, Inc. (TRXB) Stock Price & Analysis
TRex Bio, Inc. (TRXB) closed at USD 14.16 on Thursday, October 15, 2026, up 4.89% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 13.5; the Oct 15, 2026 session ranged USD 13.5–14.33 on volume of 88,696 shares. Market capitalization is $388.63M, with a 52-week range of USD 13.21–15.5 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TRXB.md
Key facts (TRXB)
- Analysts: None.
- Total return with dividends: 1Y +1.1% vs S&P 500 +18.1%; 5Y +1.1% vs S&P 500 +85.1%.
Analysts (TRXB)
Consensus None.
Total return (dividends reinvested) (TRXB)
| 1Y (from 2026-10-09) | 5Y (from 2026-10-05) | |
|---|---|---|
| Total return | +1.1% | +1.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 52.4% | 5.8% |
| Max drawdown | -3.8% (Oct 2026→Oct 2026) | +0.0% (→) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 14.16 |
|---|---|
| Change | ▲ 4.89% (up) |
| Previous Close | USD 13.5 |
| Open | USD 13.5 |
| Day Range | USD 13.5 – 14.33 |
| 52-Week Range | USD 13.21 – 15.5 |
| Volume | 88,696 shares |
| Market Cap | $388.63M |
| Exchange | NMS |
Analyst Ratings (TRXB)
Wall Street analysts rate TRXB "None", per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | None |
|---|
Earnings (TRXB)
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (TRXB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0 |
| Current Ratio | 12.18 |
| Total Cash | $90.85M |
| Total Debt | $197,000 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (TRXB)
Nexqual rates TRex Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Strong — $91M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$46M (TTM) |
| Efficiency | Mixed — No data |
Ownership (TRXB)
| Insider Ownership | +1.74% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 27.45M |
| Float | 3.16M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (TRXB)
TRex Bio, Inc. is led by Marion Johnston Erwin (age 64), Chairman & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman & CEO | Marion Johnston Erwin (age 64) |
|---|---|
| Chief Operating Officer | Laura Berner (age 50) |
| Chief Scientific Officer & Executive Director of Drug Discovery | Ali Zarrin (age 61) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt